Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Clinical and experimental dermatology - 46(2021), 8 vom: 30. Dez., Seite 1610-1612 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramessur, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1400-61-9 |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ced.14819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327366389 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327366389 | ||
| 003 | DE-627 | ||
| 005 | 20231225200628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ced.14819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327366389 | ||
| 035 | |a (NLM)34189756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramessur, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Nystatin |2 NLM | |
| 650 | 7 | |a 1400-61-9 |2 NLM | |
| 650 | 7 | |a Clobetasol |2 NLM | |
| 650 | 7 | |a ADN79D536H |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a Neomycin |2 NLM | |
| 650 | 7 | |a I16QD7X297 |2 NLM | |
| 700 | 1 | |a Saffar, N |e verfasserin |4 aut | |
| 700 | 1 | |a Czako, B |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, A |e verfasserin |4 aut | |
| 700 | 1 | |a Batta, K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental dermatology |d 1993 |g 46(2021), 8 vom: 30. Dez., Seite 1610-1612 |w (DE-627)NLM000126810 |x 1365-2230 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:8 |g day:30 |g month:12 |g pages:1610-1612 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ced.14819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 8 |b 30 |c 12 |h 1610-1612 | ||